MNPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MNPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Monopar Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.
Monopar Therapeutics's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).
The historical data trend for Monopar Therapeutics's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial | - | - | - | - | - |
Monopar Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial | - | - | - | - | - |
Monopar Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
LT Debt to Total Assets (A: Dec. 2023 ) | = | Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 ) | / | Total Assets (A: Dec. 2023 ) |
= | 0 | / | 7.345 | |
= |
Monopar Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
LT Debt to Total Assets (Q: Mar. 2024 ) | = | Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 ) | / | Total Assets (Q: Mar. 2024 ) |
= | 0 | / | 8.912 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics (NAS:MNPR) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Thank you for viewing the detailed overview of Monopar Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J Brown | director | C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211 |
Arthur J Klausner | director | ONE PALMER SQUARE, PRINCETON NJ 08542 |
Raymond Anderson | director | C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Kim R Tsuchimoto | officer: Chief Financial Officer | C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Chandler Robinson | director, officer: Chief Executive Officer | C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Andrew Cittadine | officer: Chief Operating Officer | C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091 |
Patrice Rioux | other: Acting Chief Medical Officer | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Christopher M Starr | director | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Filho Jose Octavio Pinto Costa | officer: Chief Medical Officer | C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091 |
Tactic Pharma Llc | 10 percent owner | C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Diane Hendricks | 10 percent owner | C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801 |
Karl Leo | 10 percent owner | C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801 |
Kirsten Anderson | officer: SVP, Clinical Development | C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Gem Pharmaceuticals Llc | 10 percent owner | C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Tacticgem Llc | 10 percent owner | 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-01-2022
By GlobeNewswire GlobeNewswire • 03-27-2023
By Marketwired • 08-10-2023
By PurpleRose PurpleRose • 08-11-2022
By GuruFocusNews GuruFocusNews • 06-11-2022
By sperokesalga sperokesalga • 03-23-2023
By sperokesalga sperokesalga • 03-28-2023
By GuruFocus Research • 11-09-2023
By Marketwired • 06-21-2023
By Marketwired • 07-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.